Obesity has been identified as a major risk factor for such cancer sites as colon, renal, breast, and endometrium ([Bianchini *et al*, 2002](#bib4){ref-type="other"}; [Calle and Kaaks, 2004](#bib7){ref-type="other"}; [Rapp *et al*, 2005](#bib29){ref-type="other"}), whereas hypertriglyceridemia is relevant to obesity and insulin resistance ([Despres and Lemieux, 2006](#bib10){ref-type="other"}). Dietary fat intake is a well-established risk factor in cardiovascular diseases (CVDs), in which much investigation has involved serum triglyceride (STG) concentrations ([Sarwar *et al*, 2007](#bib34){ref-type="other"}). The combination of hypertriglyceridemia and elevated waist circumference has been identified as a phenotype for higher risk of CVD ([Kahn and Valdez, 2003](#bib17){ref-type="other"}). Usually, fasting triglyceride concentrations are measured, as they are associated with increased mortality and CVD risk ([Brunzell, 2007](#bib6){ref-type="other"}). However, there is uncertainty with regard to the impact of STG concentrations on risk of CVD ([Gotto, 1998](#bib15){ref-type="other"} and also with regard to whether fasting level influences the relationship ([Langsted *et al*, 2008](#bib22){ref-type="other"}). Beyond lipid metabolism there is evidence that hypertriglyceridemia is associated with frequent infections and inflammation ([Khovidhunkit *et al*, 2004](#bib18){ref-type="other"}; [Esteve *et al*, 2005](#bib11){ref-type="other"}).

A few cohort studies have investigated high STG concentrations as a part of the metabolic syndrome ([Tulinius *et al*, 1997](#bib45){ref-type="other"}) in relation to risk of colon ([Saydah *et al*, 2003](#bib36){ref-type="other"}; [Ahmed *et al*, 2006](#bib2){ref-type="other"}, [Tande *et al*, 2006](#bib43){ref-type="other"}), breast ([Vatten and Foss, 1990](#bib47){ref-type="other"}; [Furberg *et al*, 2004](#bib13){ref-type="other"}), and cervix cancers ([Cust *et al*, 2007](#bib9){ref-type="other"}). A cohort study among Icelanders ([Tulinius *et al*, 1997](#bib45){ref-type="other"}) revealed associations between high STG levels and colorectal cancers in both sexes, and also with thyroid cancer in men, as well as with cervix, endometrial, and bladder cancer in women ([Tulinius *et al*, 1997](#bib45){ref-type="other"}).

We therefore investigated the associations between fasting STG concentrations and cancer risk in a large prospective cohort study.

Methods
=======

Study population
----------------

Details of the Vorarlberg Health Monitoring and Promotion Program (VHM&PP) in Vorarlberg, the most western region in Austria, are provided elsewhere ([Rapp *et al*, 2005](#bib29){ref-type="other"}). In brief, the Agency of Social and Preventive Medicine annually offered to all adults living in Vorarlberg a screening examination that includes a physical examination, a blood test, and a consultation with a doctor. By 2005, ∼56% of all Vorarlberg residents underwent at least one examination in this voluntary screening programme. Between 1988 and 2003, over 156 000 adult Vorarlberg residents were enrolled in the cohort after signing an informed consent form to store and process personal data and biological samples.

For the current analysis, we used a data set with complete data on STG and covariates at baseline. Participants with follow-up \<1 year (*n*=6188), or with prevalent cancer (other than non-melanoma skin cancer), were excluded before enrolment or within 1 year after enrolment (*n*=2149).

Two central laboratories, with regular internal and external quality tests, determined STG concentrations on fasting blood samples. Within 60--240 min of venous blood sample collection from a cubital vein, serum was obtained by centrifugation for 15 min at 4000 r.p.m. Subsequently, STG concentrations were measured at 37°C and were expressed as mg per 100 ml. To check calibration, three daily control samples were included. If average values of control samples of each run were not within 3% of the true value, the run was repeated. Day-by-day variation had to be within 5%. Study participants are classified according to the quartiles of STG concentrations with the following cutoff values: ⩽83, 84--119, 120--179, and ⩾180 mg 100 ml for men and ⩽69, 70--94, 95--133, and ⩾134 mg 100 ml for women. Participants in the 1st quartile were used as reference category.

Measurements of height, weight, blood pressure, total cholesterol, blood glucose, and gamma-glutamyltransferase (GGT) were obtained routinely for each participant. BMI was calculated by height and weight at baseline and was categorised on the basis of clinical guidelines (\<25 kg m^--2^, 25 to \<30 kg m^−2^, ⩾30.0 kg m^−2^) ([World Health Organisation, 1998)](#bib49){ref-type="other"}. Smoking status was classified as current, former, or non-smokers. Participants who never smoked could not be distinguished from those who did not respond to questions with regard to smoking at baseline, but baseline smoking status was verified for \>70% of study participants on the basis of information provided at subsequent examinations. As a proxy for socioeconomic position, the occupational group (blue collar, white collar, or self-employed) was determined by the participant\'s insurance number. Retired participants were classified according to their former occupation, and housewives on the basis of the job of their spouse.

As described previously in detail ([Rapp *et al*, 2005](#bib29){ref-type="other"}), cancer cases were identified by record linkage with the Vorarlberg cancer registry, which has been accepted for IARC publication since 1993 ([Parkin DM *et al*, 2003](#bib28){ref-type="other"}) and has high completeness of ascertainment ([Oberaigner W, 2006](#bib26){ref-type="other"}). In the Vorarlberg cancer registry, nearly all cancers (96.7%) were histologically verified and the Death-certificate-only (DCO) rate meets international quality criteria (5% for both sexes in 1998--2002). Cohort data were linked to the Vorarlberg Death Index to identify deaths and to calculate person-years. The current analysis makes use of the data set updated at the end of 2003. The average follow-up time was 10.6 (s.d. 4.5) years. The 10th Revision of the *International Statistical Classification of Diseases, Injuries and Causes of Death* (ICD) was used to code the cancers ([World Health Organization, 2008](#bib50){ref-type="other"}).

Statistical analysis
--------------------

The analytical cohort comprised 156 153 subjects (71 693 men and 84 460 women). Partial correlation coefficients were calculated to examine the relationship between STG and other clinical parameters. Cox proportional hazard models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for quartiles relative to the reference group (1st quartile of STG level). Models were adjusted for serum concentrations of glucose (mg per 100 ml, continuous)([Rapp *et al*, 2006](#bib30){ref-type="other"}), total cholesterol (mg per 100 ml, continuous) ([Ulmer *et al*, 2004](#bib46){ref-type="other"}; [Strasak *et al*, 2009](#bib38){ref-type="other"}), GGT (U l^--1^, continuous) ([Strasak *et al*, 2008a](#bib39){ref-type="other"},[2008b](#bib40){ref-type="other"}), body mass index (BMI, kg m^−2^, continuous) ([Rapp *et al*, 2005](#bib29){ref-type="other"}), occupational status, and smoking status (both in classes). Continuous risk estimates are presented for an increase in exposures of one unit log-transformed STG concentration. To test the overall significance of exposure, *P*-values for Wald *χ*^2^ statistics are shown. As no obvious sex differences between the estimates emerged, models were calculated for the sexes combined. All *P*-values are two-sided and all calculations were carried out with SAS statistical software package SAS release 9.1 (SAS Institute, Cary, NC, USA).

Results
=======

During follow-up, 5079 incident invasive cancer cases among men and 4738 incident invasive cancer cases among women were identified ([Table 1](#tbl1){ref-type="table"}). Correlations between BMI, age, and serum concentrations of STG, total cholesterol, glucose, and GGT are shown in [Table 2](#tbl2){ref-type="table"}. STG was weakly associated with serum glucose concentrations and moderately associated with BMI, total cholesterol, and GGT concentrations.

[Table 3](#tbl3){ref-type="table"} shows the hazard ratios for cancer type by STG concentrations in the VHM&PP cohorts. Compared with the 1st quartile, high STG concentrations (4th quartile) were associated with increased risk of lung (HR, 1.94; 95% CI, 1.47--2.54), rectal (HR, 1.56; 95% CI, 1.00--2.44), and thyroid cancer (HR, 1.96; 95% CI, 1.00--3.84). High STG concentrations were inversely associated with non-Hodgkin\'s lymphoma. Prostate cancer was inversely associated with STG concentrations (per log-unit HR, 0.80; 95% CI, 0.72--0.90) and was positively associated with incidence of kidney cancer in men (data not shown). High STG concentrations were associated with higher overall cancer risk (4th *vs* 1st quartile: HR, 1.19; 95% CI, 1.05--1.33) and with risk of gynaecological cancers (endometrium, ovar, cervix) (4th *vs* 1st quartile: HR, 1.62; 95% CI, 1.13--2.33).

[Figure 1](#fig1){ref-type="fig"} shows HRs for selected cancers by STG concentrations stratified by BMI. These did not reveal differential associations of STG levels with cancer overall, or with lung and colon cancer risk; however, the risk of gynaecological cancers was higher in overweight than in normal weight women. When data were stratified by smoking status (data not shown), no differential estimates emerged for overall and gynaecological cancers, but a somewhat higher risk of rectal cancer was found in current smokers (*N*=50 cases; per log-unit HR, 1.73; 95% CI, 1.02--2.92) than in non-smokers (*N*=177 cases; per log-unit HR, 1.11; 95% CI, 0.79--1.56), and a higher risk of lung cancer was found in non-smokers (*N*=222 cases; per log-unit HR, 1.57; 95% CI, 1.19--2.06) than in smokers (*N*=334 cases; per log-unit HR, 1.13; 95% CI, 0.91--1.39). However, no significant effect modification by BMI and smoking status was found. Stratification by GGT levels (⩽30 and \>30 U l^−1^) revealed differential relationships between STG and overall cancer risk and lung cancer (data not shown).

Discussion
==========

In this large-scale cohort study, high STG concentrations were associated with higher overall cancer risk in women, but not in men. In men and women combined, STG concentrations were related to high risk of lung, thyroid, and rectal cancer. In men, STG concentrations were associated inversely with prostate cancer, and in women they were associated positively with gynaecological cancers. Our findings regarding lung, rectal, and gynaecological cancers are consistent with data using dietary fat intake levels as exposure variable ([Kushi and Giovannucci, 2002](#bib21){ref-type="other"}; [Genkinger *et al*, 2006](#bib14){ref-type="other"}).

Our observation of a positive association between STG levels and rectal cancer is in line with previous findings in a cohort study among Icelanders ([Tulinius *et al*, 1997](#bib45){ref-type="other"}). Further evidence for a relationship with STG comes from case--control studies on colorectal adenoma ([Kono *et al*, 1990](#bib19){ref-type="other"}; [Bird *et al*, 1996](#bib5){ref-type="other"}; [Otani *et al*, 2006](#bib27){ref-type="other"}; [Tabuchi *et al*, 2006](#bib41){ref-type="other"}), carcinoma *in situ* ([Yamada *et al*, 1998](#bib52){ref-type="other"}), and from an *in-vitro* study ([Tabuchi *et al*, 2008](#bib42){ref-type="other"}). It has been suggested that total cholesterol, STG, and plasma glucose are positively associated with colorectal cancer risk ([Yamada *et al*, 1998](#bib52){ref-type="other"}). In our study, the association occurred adjusted for plasma glucose and total cholesterol concentrations. In men and women combined, we observed an association between STG concentration and rectal cancer risk, whereas no association was found for colon cancer, neither was any association found in sex-stratified analyses. Consistent with a study among Japanese-American men ([Tsushima *et al*, 2005](#bib44){ref-type="other"}) and US prospective studies ([Saydah *et al*, 2003](#bib36){ref-type="other"}; [Ahmed *et al*, 2006](#bib2){ref-type="other"}), we did not find a relationship with colorectal cancer.

Our findings of high lung cancer risk among subjects with high STG concentrations are unique. In one study, an association between total cholesterol and lung cancer risk has been observed, suggesting a relationship between lipid metabolism and lung cancer risk ([Hinds *et al*, 1983](#bib16){ref-type="other"}). In the Carotene and Retinol Efficacy Trial (CARET), among the participants receiving *β*-carotene and retinol, higher serum triglyceride concentrations were observed ([Cartmel *et al*, 2005](#bib8){ref-type="other"}), suggesting a relationship between STG and lung cancer risk. As smoking is associated with higher STG concentrations ([Brunzell, 2007](#bib6){ref-type="other"}), residual confounding due to smoking may contribute to the association between STG concentrations and lung cancer risk. In our study, however, the association persisted when the data set was limited to non-smokers, suggesting that factors other than smoking status may contribute to the observed association. The limited differentiation between missing smoking data and non-smoking status may have resulted in misclassification of smoking status. However, smoking information from follow-up visits for most of the participants was used to complement the baseline smoking status.

The positive association with thyroid cancer risk is in line with findings in a cohort study ([Tulinius *et al*, 1997](#bib45){ref-type="other"}). It may be relevant that BMI was positively associated with thyroid cancer ([Renehan *et al*, 2008](#bib31){ref-type="other"}).

In our study, STG concentrations were inversely associated with prostate cancer risk, in contrast to the reverse findings in a case--control study ([Wuermli *et al*, 2005](#bib51){ref-type="other"}). However, in this clinical-based study, prostate cancers were compared with benign prostate hyperplasia, in which STG levels were lower than those in cancer cases. In large cohort studies in Norway and the United States, no association between STG and prostate cancer risk was found ([Lund *et al*, 2006](#bib24){ref-type="other"}; [Tande *et al*, 2006](#bib43){ref-type="other"}). The application of prostate-specific antigen contributes to heterogeneity of phenotype ([Etzioni *et al*, 2002](#bib12){ref-type="other"}), which may have distorted the relationship with STG. In addition, an inverse relationship for NHL was observed in our study. Previous reports on cholesterol indicted that reverse causation may substantially contribute to the risk-lowering effect of high blood lipids ([Rose and Shipley, 1980](#bib32){ref-type="other"}; [Lim *et al*, 2007](#bib23){ref-type="other"}; [Strasak *et al*, 2009](#bib38){ref-type="other"}).

Our observation that STG concentrations were positively associated with kidney cancer incidence in men (data not shown) contrasts with a recently published meta-analysis on BMI and renal cancer risk ([Renehan *et al*, 2008](#bib31){ref-type="other"}). However, in our study, after adjusting for diastolic blood pressure, an established risk factor for renal cancer (per log-unit HR, 1.26; 95% CI, 0.95--1.68), the association was no longer statistically significant. For men and women combined, we found no statistically significant association between STG and kidney cancer risk.

Our observation of a positive association of STG concentrations with risk of gynaecological cancers (cervix, ovary, endometrial) is consistent with other studies ([Tulinius *et al*, 1997](#bib45){ref-type="other"}; [Cust *et al*, 2007](#bib9){ref-type="other"}). In one study, increasing triglyceride and glucose concentrations were associated with increased endometrial cancer risk ([Cust *et al*, 2007](#bib9){ref-type="other"}). Our findings on cervical cancer are in line with those in a cohort study ([Tulinius *et al*, 1997](#bib45){ref-type="other"}). For breast cancer, inconsistent results have been reported from a nested case--control study ([Agnoli *et al*, 2009](#bib1){ref-type="other"}) and from cohort studies ([Vatten and Foss, 1990](#bib47){ref-type="other"}; [Furberg *et al*, 2004](#bib13){ref-type="other"}).

These associations with gynaecological cancer raise a question with regard to the involvement of oestrogens, which are considered to stimulate hepatic triglyceride secretion ([Sattler *et al*, 2005](#bib35){ref-type="other"}), as confirmed by studies on hormone replacement therapy ([Rossouw *et al*, 2008](#bib33){ref-type="other"}; [Sowers *et al*, 2008](#bib37){ref-type="other"}).

High STG concentrations may reflect other metabolic aspects that are procarcinogenic ([McKeown-Eyssen, 1994](#bib25){ref-type="other"}). Associations between STG and plasma glucose levels are well established and hyperglycaemia is a risk factor for several cancers ([Ashley and Kannel, 1974](#bib3){ref-type="other"}). In our study, however, we used fasting STG levels and adjusted for plasma glucose levels to control for confounding by glucose levels. Inflammation is another potential mechanism by which hypertriglyceridemia is associated with cancer risk ([Esteve *et al*, 2005](#bib11){ref-type="other"}; [Kundu and Surh, 2008](#bib20){ref-type="other"}). STG concentrations may be linked to colorectal cancer risk by bile acid excretion, circulation hormones, or energy supply to neoplastic cells ([McKeown-Eyssen, 1994](#bib25){ref-type="other"}).

A limitation of our study is the lack of information on such potential risk factors as alcohol consumption and physical activity. However, the results of our multivariate models adjusted for GGT concentrations may be considered as a proxy variable for alcohol intake ([Whitehead *et al*, 1978](#bib48){ref-type="other"}). In addition, no information on medication history (for example, on lipid-lowering drugs or hormones) was available, which may have affected the associations observed. Among women, the effect of STG may be overestimated because of residual confounding by exogenous hormones, whereas for lipid-lowering medications, the opposite could be relevant.

Undocumented measurement variation in STG concentrations during the study period may also have affected our results, but we assume that these were minor, as we used fasting STG levels. The strengths of our study are large sample size, prospective design, length of follow-up, and standardised examinations by trained physicians. It is relevant that the study population is relatively young and healthy.

Overall, STG concentrations were positively associated with the risk of lung, thyroid, and rectal cancers, but inversely with NHL risk. Prostate cancer risk was inversely associated with STG concentrations, whereas positive associations were found with renal cancer among men and with gynaecological cancers among women. Our results suggest that STG concentrations are involved in the pathogenesis of several cancer sites.
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###### 

Characteristics of the study population (*N*=156 153) by quartile of serum triglyceride (STG) concentration

                                                               **All**               **1st quartile**    **2nd quartile**    **3rd quartile**       **4th quartile**
  ------------------------------------------------------------ --------------------- ------------------- ------------------- ---------------------- ----------------------
  Triglycerides (mg 100 ml^−1^), median (Q1, Q3)               104.0 (74.0, 152.0)   61.0 (52.0, 68.0)   88.0 (81.0, 96.0)   124.0 (114.0, 137.0)   207.0 (175.0, 269.0)
  Total cholesterol (mg 100 ml^−1^), mean (s.d.)               213.7 (45.8)          188.8 (36.3)        206.1 (39.2)        220.0 (41.7)           240.9 (48.5)
  Glucose (mg 100 ml^−1^), mean (s.d.)                         87.2 (22.6)           83.7 (16.3)         85.0 (20.0)         87.2 (21.0)            93.0 (31.2)
  Gamma-glutamyltransferase (GGT) (U l^−1^), median (Q1, Q3)   12.0 (8.0, 18.0)      9.0 (7.0, 13.0)     11.0 (8.0, 15.0)    12.0 (9.0, 19.0)       18.0 (12.0, 29.0)
  Age (years), mean (s.d.)                                     41.8 (15.1)           37.2 (13.0)         40.8 (15.1)         43.4 (15.9)            50.0 (14.9)
  BMI (kg m^−2^), mean (s.d.)                                  24.7 (4.2)            22.9 (3.4)          24.1 (3.9)          25.2 (4.3)             30.0 (4.3)
  Current smokers (%)                                          25.2                  20.4                23.7                26.1                   30.8
  Occupational status: white collar (%)                        54.3                  58.3                56.1                53.3                   49.3

###### 

Correlation of serum triglyceride (STG) concentrations with other clinical measures in the study population

  **Covariates**                              **Correlation coefficients**^**a**^   ***P*-value**
  ------------------------------------------- ------------------------------------- ---------------
  BMI (kg m^−2^)                              0.30                                  \<0.001
  Total cholesterol (mg 100 ml^−1^)           0.41                                  \<0.001
  Glucose (mg 100 ml^−1^)                     0.14                                  \<0.001
  Gamma-glutamyltransferase (GGT) (U l^−1^)   0.32                                  \<0.001

Age- and sex- adjusted partial correlation coefficients, STG, and GGT were log transformed.

###### 

Hazard ratios (HR with 95% CI) and numbers of cases for cancers by site and STG quartiles^a^

  **Cancer site of both sexes ICD-10 codes**    **Total no. of cases**   **1st quartile**       **2nd quartile**            **3rd quartile**            **4th quartile**       **Total per log-unit increase**   ***P*-value for log unit increase**
  -------------------------------------------- ------------------------ ------------------ --------------------------- --------------------------- --------------------------- --------------------------------- -------------------------------------
  Thyroid C73                                          \(101\)             \(16\) 1.00      \(25\) 1.55 (0.82--3.00)    \(30\) 1.84 (0.97--3.48)    \(30\) 1.96 (1.00--3.84)   1.16 (0.76--1.76)                 0.492
  Plasmacytoma C90                                      \(73\)              \(7\) 1.00      \(19\) 1.88 (0.74--4.78)    \(16\) 1.37 (0.52--3.59)    \(31\) 2.11 (0.82--5.43)   1.39 (0.84--2.31)                 0.204
  NHL C82--C85                                         \(219\)             \(42\) 1.00      \(61\) 0.99 (0.66--1.49)    \(54\) 0.71 (0.46--1.07)    \(62\) 0.68 (0.43--1.07)   0.71 (0.52--0.97)                 0.033
  Stomach C16                                          \(315\)                \(41\)        \(80\) 1.32 (0.90--1.95)    \(83\) 1.22 (0.83--1.82)    \(111\) 1.45 (0.97--2.17)  1.17 (0.92--1.49)                 0.208
  Pancreatic C25                                       \(162\)             \(24\) 1.00      \(35\) 0.99 (0.58--1.69)    \(39\) 0.86 (0.50--1.47)    \(64\) 1.19 (0.70--2.05)   1.25 (0.90--1.75)                 0.188
  Colon C18                                            \(600\)             \(81\) 1.00      \(122\) 0.93 (0.70--1.23)   \(175\) 1.05 (0.80--1.39)   \(222\) 1.08 (0.81--1.43)  1.06 (0.88--1.26)                 0.547
  Rectal C19/20                                        \(273\)             \(32\) 1.00      \(69\) 1.47 (0.95--2.26)     \(69\) 1.25 (0.81--1.94    \(103\) 1.56 (1.00--2.44)  1.20 (0.92--1.55)                 0.184
  Bladder C67                                          \(158\)             \(24\) 1.00      \(36\) 1.50 (0.48--4.71)    \(59\) 0.73 (0.22--2.46)    \(39\) 1.42 (0.45--4.43)   1.03 (0.98--1.09)                 0.218
  Kidney C64                                           \(216\)             \(35\) 1.00      \(40\) 0.81 90.51--1.280    \(51\) 0.88 (0.57--1.38)    \(90\) 1.27 (0.81--1.97)   1.27 (0.95--1.69)                 0.105
  Lung C34                                             \(650\)             \(86\) 1.00      \(128\) (1.12 0.85--1.48)   \(179\) (1.43 1.09--1.87)   \(257\) (1.94 1.47--2.54)  1.50 (1.28--1.75)                 \<0.0001
                                                                                                                                                                                                                  
  *Men*                                                                                                                                                                                                          
   Prostate C61                                        \(1484\)            \(304\) 1.00     \(397\) 0.94 (0.80--1.09)   \(470\) 0.87 (0.75--1.02)   \(353\) 0.67 (0.56--0.80)  0.80 (0.72--0.90)                 \<0.001
                                                                                                                                                                                                                  
  *Women*                                                                                                                                                                                                         
   Breast C50 ⩽50 years                                \(510\)             \(127\) 1.00     \(157\) 1.25 (0.98--1.59)   \(136\) 1.23 (0.95--1.59)   \(90\) 0.95 (0.70--1.28)   0.92 (0.74--1.15)                 0.455
  Breast \>50 years                                    \(694\)             \(75\) 1.00      \(135\) 0.93 (0.70- 1.24)     200 1.00 (0.76--1.32)       284 1.05 (0.79--1.39)    1.09 (0.91--1.30)                 0.352
  Cervical C53                                          \(70\)             \(12\) 1.00      \(17\) 1.48 (0.69--3.19)    \(18\) 1.52 (0.70--3.34)    \(23\) 2.00 (0.89- 4.50)   1.74 (1.03--2.95                  0.038
  Endometrium C54                                      \(236\)             \(22\) 1.00      \(50\) 1.38 (0.83--2.30)    \(54\) 1.11 (0.66--1.86)    \(110\) 1.61 (0.97--2.67)  1.22 (0.90--1.65)                 0.206
  Ovarian C56                                          \(123\)                \(16\)        \(29\) 1.57 (0.81--3.04)    \(39\) 1.75 (0.91--3.37)    \(39\) 1.43 (0.71--2.85)   1.13 (0.74--1.74)                 0.576
  Gynaecological (C53, 54, 56)                         \(429\)             \(50\) 1.00      \(96\) 1.45 (1.01- 2.07)    \(111\) 1.35 (0.94--1.93)   \(172\) 1.62 (1.13--2.33)  1.26 (1.01--1.58)                 0.042

Adjusted for BMI (kg m^−2^, continuous), GGT (continuous), serum glucose (continuous), total cholesterol concentration (continuous), smoking status, and occupational status.

[^1]: These authors contributed equally to this work.
